Jeremiah H Nguyen

This inventor holds 27 USPTO granted patents and 2 published patent applications, plus 5 CIPO patents and 11 EPO patents, primarily in Therapeutic Compounds. Top assignees: Allergan, Inc., Other. Active years: 2006-2021.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Jeremiah H Nguyen. Retrieved from https://idiyas.com/inventor/jeremiah-h-nguyen

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 27 (Patent Applications = 2)

% Patents Active = 70.4

CIPO Patents = 5 (Patent Applications = 1)

EPO Patents = 11 (Patent Applications = 13)

Average Co-Inventor Count = 2.5

ph-index = 3

Forward Citations = 91(Granted Patents)

Company Filing History:

26 out of 2,287

Allergan, Inc.

patents

1 out of 834,570

Other

patents

Years Active: 2006-2021

Loading Chart...

Areas of Expertise:

Therapeutic Compounds

Cyclopentanes

Arylcyclopentenes

Prostaglandin Agonists

Inflammatory Bowel Disease

Skin Repair

Prostaglandin Activity

Therapeutic Agents

Amidoalkylenyl Esters

Cyclopentanones

Geminal Dialkyl Prostanoids

Therapeutic Derivatives

27 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11208377 - 3,4-disubstituted 3-cyclobutene-1,2-diones and use thereof (2021-12-28),

2. 9796696 - Substituted arylcyclopentenes as therapeutic agents (2017-10-24),

3. 9637467 - Treatment of inflammatory bowel disease (2017-05-02),

4. 9573926 - Amidoalkylenyl and amidoaryl esters, compositions thereof, and methods for their use (2017-02-21),

5. 9546162 - Compounds and methods for skin repair (2017-01-17),

6. 9394273 - Therapeutic prostaglandin receptor agonists (2016-07-19),

7. 9365485 - Substituted arylcyclopentenes as therapeutic agents (2016-06-14),

8. 9156810 - Treatment of inflammatory bowel disease (2015-10-13),

9. 9006464 - Substituted cyclopentanes having prostaglandin activity (2015-04-14),

10. 9000032 - Substituted cyclopentenes as therapeutic agents (2015-04-07),

11. 8754122 - Geminal dialkyl prostanoids (2014-06-17),

12. 8722726 - Substituted arylcyclopentenes as therapeutic agents (2014-05-13),

13. 8530471 - Therapeutic cyclopentane derivatives (2013-09-10),

14. 8299068 - Therapeutically active cyclopentanes (2012-10-30),

15. 8278347 - Therapeutic compounds (2012-10-02),

Title: Jeremiah H Nguyen: A Prolific Innovator in Pharmaceutical Patents

Introduction

Jeremiah H Nguyen, based in La Puente, California, is a distinguished inventor recognized for his contributions to the pharmaceutical industry with a remarkable portfolio of 27 patents. His work, particularly in the realm of therapeutic compounds, has made significant strides in the treatment of various inflammatory and autoimmune diseases.

Latest Patents

Nguyen's latest innovations include two noteworthy patents:

1. **3,4-disubstituted 3-cyclobutene-1,2-diones and use thereof** - This patent describes compounds, or pharmaceutically acceptable salts, effective for treating inflammatory and autoimmune diseases.

2. **Substituted arylcyclopentenes as therapeutic agents** - This patent discloses compounds and outlines therapeutic methods, compositions, and medicaments related to them.

Career Highlights

Throughout his career, Jeremiah H Nguyen has been associated with leading pharmaceutical companies, including Allergan, Inc. His work has been pivotal in advancing the field of therapeutics and enhancing the efficacy of treatments available for complex medical conditions.

Collaborations

Nguyen has collaborated with notable professionals in his field, including Yariv Donde and Robert M Burk. These collaborations have underscored his commitment to innovation and have contributed to the successful development of new therapeutic agents.

Conclusion

Jeremiah H Nguyen’s profound impact on the pharmaceutical landscape is evident through his numerous patents and collaborative efforts. His ongoing work continues to open new avenues for treatment and underscores the importance of innovation in addressing pressing health challenges.

Profile summary based on public USPTO records.